Search Medical Condition
Please enter condition
Please choose location from dropdown

Herston, Australia Clinical Trials

A listing of Herston, Australia clinical trials actively recruiting patients volunteers.

Found (372) clinical trials

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care …

Phase N/A

0.27 miles

Learn More »

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are …

Phase

0.27 miles

Learn More »

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, an …

Phase

0.27 miles

Learn More »

Plasma-Lyte 148 versUs Saline Study

Fluid resuscitation is a fundamental component of the management of acutely and critically ill patients and the choice of fluid is a longstanding issue of debate. Worldwide, 0.9% saline has traditionally been the most widely used resuscitation fluid, however its use is increasingly challenged by emerging evidence that suggests its …

Phase

0.27 miles

Learn More »

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

For Groups 1 to 4, the primary objective of this study is to estimate the clinical benefit of cemiplimab monotherapy for patients with: metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable locally advanced CSCC. For Group 6, the primary objective is to provide additional efficacy and safety …

Phase

0.27 miles

Learn More »

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma

Renal cell carcinoma (RCC) is the 9th most common cancer in Australia, the 10th most common cancer in Western populations1. Approximately 75% of kidney cancers are clear-cell renal cell carcinomas (ccRCC). Current treatments for metastatic ccRCC include VEGFR tyrosine kinase inhibitors (TKIs) and mTOR inhibitors and while many patients benefit …

Phase

0.27 miles

Learn More »

A Trial of KB004 in Patients With Glioblastoma

This is a study of drug KB004 in patients with recurrent glioblastoma (GBM). Eligible patients with measurable tumours will receive an initial trace (5mg) dose of zirconium labelled KB004 (89ZrKB004) on day 1 followed by sequential Positron emission tomography (PET) imaging over 1 week to determine its biodistribution into GBM …

Phase

0.27 miles

Learn More »

Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

The purpose of this project is to test the addition of a new treatment called denosumab to standard immunotherapies for patients with metastatic melanoma. Denosumab has been used for many years to help treat cancers such as prostate cancer and breast cancer, but it is not currently used in melanoma. …

Phase

0.27 miles

Learn More »

Study of SAR339375 in Patients With Alport Syndrome

The planned length of participation in the study for each subject is up to approximately 106 weeks (from screening through completion of follow-up). This includes: Screening/baseline period of up to 4 weeks Double-blind, placebo-controlled treatment period of 48 weeks Open-label extension treatment period of 48 weeks ( opportunity for all …

Phase

0.27 miles

Learn More »

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation Radiation Therapy and/or Surgery in Treating Patients With Ewing's Sarcoma

OBJECTIVES: Primary - Compare the event-free and overall survival of patients with tumor of the Ewing's family treated with standard induction chemotherapy comprising vincristine, dactinomycin, ifosfamide and etoposide (VIDE) followed by consolidation chemotherapy comprising vincristine, dactinomycin, and ifosfamide versus high-dose busulfan and melphalan (Bu-Mel) followed by autologous peripheral blood stem …

Phase

0.27 miles

Learn More »